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Background: YKL-40, a mammalian member of chitinase-like proteins, has been shown to play
a role in pathological conditions leading to tissue remodeling and fibrosis. Recently, YKL-40 was
found to be increased in severe asthma, suggesting that YKL-40 contributes to airway remodel-
ing; however, no data are available about YKL-40 expression in idiopathic pulmonary fibrosis
(IPF). The present study was conducted to investigate YKL-40 expression in the serum and lung
of IPF patients, and to determine its clinical significance.
Methods: Using an enzyme-linked immunosorbent assay, we measured YKL-40 levels in the
serum of 63 IPF patients and in bronchoalveolar lavage fluid (BALF) of 18 IPF patients. YKL-
40 levels were also assessed in the serum and BALF of healthy subjects. We further investi-
gated the relationship between serum YKL-40 levels and clinical parameters. Additionally,
immunohistochemical staining for YKL-40 was performed in lung specimens of IPF patients
and control subjects.
Results: Serum and BALF YKL-40 levels were significantly higher in IPF than in controls (serum:
245.8  180.2 ng/ml vs. 116.0  58.3 ng/ml; BALF: 17.8  19.1 ng/ml vs. 0.3  0.9 ng/ml,
respectively). Serum YKL-40 levels significantly correlated positively with serum KL-6 levels
and AaDO2, and negatively with DLco and PaO2. Immunohistochemical study revealedlavage; BALF, bronchoalveolar lavage fluid; DLco, carbon monoxide diffusing lung capacity; IPF,
lactate dehydrogenase; SP-D, surfactant protein D; VC, vital capacity; YKL-40, human cartilage
3)435 2263; fax: þ81(53)435 2354.
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YKL-40 in serum and lung of patients with IPF 1205enhanced YKL-40 expression in alveolar macrophages and bronchiolar epithelia adjacent to
fibrotic lesions in IPF, but not in controls.
Conclusions: These data suggest that YKL-40 is increased in the circulation and lungs of IPF
patients, suggesting that this glycoprotein is associated with the pathophysiology of IPF.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive, diffuse
parenchymal lung disease of unknown etiology with signif-
icant morbidity and mortality. A heterogeneous fibrosing
process is one of the most characteristic pathologic
features of IPF.1 The pathogenesis of IPF is believed to
result from a miscommunication between epithelial and
mesenchymal cells, which leads to abnormal tissue
remodeling.2 This process is driven by the presence of
soluble factors, such as cytokines, chemokines, and growth
factors3; however, not all factors promoting the fibrotic
process in IPF have been confirmed.
YKL-40, also called human cartilage glycoprotein 39
(HCgp-39) and chitinase 3-like 1, was recently described as
a glycoprotein that belongs to the chitinase family.4 Chiti-
nase is a family of evolutionarily conserved hydrolases
characterized by its chitinase activity to cleave the envi-
ronmentally abundant polysaccharide chitin in nature.
Although mammals do not synthesize chitin, they do
synthesize chitinase. Recently studies have shown that they
do express true chitinases, including acidic mammalian
chitinase and chitotriosidase,5 and also identified the
chitinase-like protein YKL-40, which binds chitin but lacks
chitinase activity.4
Although the physiological function of YKL-40 is unknown
in detail, this glycoprotein has been shown to be a growth
factor for mesenchymal cells that contributes to tissue
remodeling and degradation of extracellular matrix.6 YKL-
40 induces the proliferation of chondrocytes and synovial
cells,7 and also potently stimulates the growth of several
types of human fibroblast derived from fetal lung, adult
skin, and synovium.8 In addition, YKL-40 acts a chemo-
attractant for endothelial cells, and modulates vascular
endothelial cell morphology by promoting the formation of
branching tubules.9 Thus, YKL-40 plays a role in angiogen-
esis by stimulating the migration and reorganization of
vascular endothelial cells. Collectively, these data suggest
that YKL-40 is involved in the pathologic process of human
diseases with tissue remodeling.
Interestingly, a recent study by Chupp et al. demonstrated
that the serum levels of YKL-40 were increased in patients
with severe asthma.10 Its levels correlated positivelywith the
thickness of the subepithelial basement membrane and
clinical indexes of disease severity. These data suggest that
increased levels of YKL-40 contribute to airway remodeling in
severe asthma. Because IPF is characterized by abnormal
tissue remodelingandfibrosis,wehypothesized thatYKL-40 is
associatedwith the pathophysiology of IPF; however, no data
arecurrently available aboutYKL-40 in IPFpatients. Thus, the
present study was conducted to investigate the expression of
YKL-40 in theserumand lungof IPFpatients, and todetermine
its clinical significance.Materials and methods
Subjects
The study subjects were 63 IPF patients, who were referred
to our institutions from 2005 to 2009 (Table 1). The diag-
nosis of IPF was based on the history, physical examina-
tions, pulmonary function studies, chest high-resolution
computed tomography (HRCT), and histologic examination.
All IPF patients met the recent America Thoracic Society
(ATS)/European Respiratory Society (ERS) criteria.11 In 22
patients, the histological diagnosis of IPF was established
by surgical lung biopsy, and the remaining 41 patients were
clinically diagnosed without biopsy confirmation, according
to the clinical criteria for IPF proposed by ATS/ERS. No
patients with asthma, COPD or collagen-vascular disease
were included. Control subjects were 41 healthy age- and
gender-matched subjects (38 men and 3 women) (Table 1).
For immunohistochemistry of YKL-40, 11 patients with
benign tumors undergoing surgical lung biopsy were also
included as a control. This study was approved by the ethics
committee of our institution, and informed consent was
obtained in accordance with institution guidelines.
Data collection
Clinical data were obtained from medical records. Labo-
ratory findings and pulmonary function tests at the time of
diagnosis were also recorded.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed as described
previously in 18 IPF patients and 16 control subjects.12 Of
22 biopsy-proven IPF patients, 8 underwent BAL. Briefly,
a fiberoptic bronchoscope was passed transorally and
wedged in a segmental or subsegmental bronchus of the
middle lobe. Three 50-ml aliquots of sterile 0.9% saline
were instilled and the returns were gently aspirated
through the side channel of the bronchoscope. BAL fluid
(BALF) was centrifuged at 800 g for 10 min to obtain the
cellular components. Supernatant was collected for
measurement of YKL-40. The total cell count was deter-
mined using a hemocytometer and a differential cell count
was taken on Giemsa-stained cytocentrifuged preparations.
Measurements of YKL-40 levels in serum and BAL
fluid
Serum and supernatant of BALF were collected at the time
of diagnosis, when none of the patients were under
systemic corticosteroid or immunosuppressive therapy, and
Table 1 Patient characteristics.
IPF (NZ 63) Controls
(NZ 41)
P-value
Gender (male/female) 60/3 38/3 NS
Age (year) 70.2 7.8a 67.5 8.5 NS
Smoking status
Current 10 9 NS
Former 46 22
Never 7 10
Diagnosis
Pathological 22 ND
Clinical 41
Serum KL-6 (U/ml) 1121.8 823.5 ND
Serum SP-D (ng/ml) 230.6 181.7 ND
Serum LDH (IU/L) 258.1 128.2 ND
VC (% predicted) 79.8 19.3 ND
DLco (% predicted) 71.1 31.3 ND
PaO2 (Torr) 81.3 11.3 ND
AaDO2 (Torr) 19.5 11.6 ND
BAL NZ 18 NZ 16
TCC (105/ml) 1.7 0.7 1.5 1.1 NS
AM (%) 88.7 10.6 91.1 9.5 NS
Lym (%) 7.8 8.6 7.2 7.8 NS
Neut (%) 1.7 2.8 1.4 1.9 NS
Eos (%) 3.1 6.2 0.3 0.4 <0.05
BAL, bronchoalveolar lavage; SP-D, surfactant protein D; LDH,
lactate dehydrogenase; VC, vital capacity; DLco, diffusion
capacity for carbon monoxide; AaDO2, alveolar-arterial oxygen
difference; TCC, total cell count; AM, alveolar macrophages;
Lym, lymphocytes; Neut, neutrophils; Eos, eosinophils.
a Average SD; NS, not significant; ND, not done.
P < 0.0001
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Figure 1 Serum YKL-40 levels of IPF patients and control
subjects. IPF patients show significantly higher serum YKL-40
levels than control subjects (p< 0.0001). The bottom and top
of the box are always the 25th and 75th percentile (the lower
and upper quartiles, respectively), and the band near the
middle of the box is the 50th percentile (the mean). Also, The
bottom and top of the bars are the lowest data still within 1.5
interquartile range (IQR) of the lower quartile, and the highest
data still within 1.5 IQR of the upper quartile. Any data not
included between the ranges are plotted as an outlier with
a dot.
1206 K. Furuhashi et al.stored at 30 C until this investigation. YKL-40 levels were
measured with an enzyme-linked immunosorbent assay
(ELISA) kit (Metra YKL-40; Quidel Corporation, San Diego,
CA), in accordance with the manufacturer’s instructions.
All samples were run in duplicate.
Immunohistochemistry for YKL-40
Lung tissues of IPF were obtained by surgical lung biopsy,
and after 10% formalin fixation, the tissues were embedded
in paraffin. Deparaffinized sections (5 mm thick) were
immersed in epitope retrieval solution (Target Retrival
Solution S1700; Dako North America, Inc., Carpinteria, CA),
and preheated to 120 C for 10 minutes. After blocking
endogenous peroxidase with 3% H2O2 for 15 minutes, the
slides were incubated with the primary rabbit anti-human
YKL-40 polyclonal antibody (1:500; Quidel) overnight at
4 C. Subsequently, the sections were incubated with
visualization reagent (Histofine simple stain MAX-PO(R);
Nichirei Co., Tokyo, Japan) for 30 minutes, and the immu-
noreaction was visualized using 3,3-diaminobenzidine
chromogen solution (DAB substrate kit; Vector Laborato-
ries, Inc., Burlingame, CA) and counterstained with hema-
toxylin. As controls, lung tissues were also taken from
different sites distant from the lesion in patients with
benign tumors.Statistical analysis
Statistical analysis was performed using the Wilcoxon/
KruskaleWallis test and Spearman’s rank correlation tech-
nique. Statistical significance was denoted by p< 0.05 for
all tests. All data are expressed as the mean SD.
Results
Patient characteristics
The clinical features and laboratory findings are summa-
rized in Table 1. The mean age of IPF patients was
70.2 7.8 years, and most were male. IPF patients showed
a increase in the mean levels of serum KL-6 and SP-D
(normal ranges, <500 U/ml and < 100 ng/ml, respec-
tively), and a decrease in mean diffuse capacity for carbon
monoxide (DLco). There were no significant differences in
gender, age, or smoking status between IPF patients and
control subjects. In BAL findings, the percentages of
eosinophils were significantly higher in IPF patients than in
control subjects.
YKL-40 levels in the serum and BALF
In the serum, YKL-40 levels were significantly higher in IPF
patients than in control subjects (245.8 180.2 ng/ml vs.
116.0 58.3 ng/ml, respectively, p< 0.0001) (Fig. 1). In
smokers, serum YKL-40 levels were significantly elevated in
IPF patients than in control subjects (271.5 49.2 ng/ml vs.
93.2 51.9 ng/ml, respectively, p< 0.01). In non-smokers,
including former and never smokers, serum YKL-40 levels
were significantly elevated in IPF patients than in control
YKL-40 in serum and lung of patients with IPF 1207subjects (240.9 19.8 ng/ml vs. 122.4 25.5 ng/ml,
respectively, p< 0.0001).
In the BALF, YKL-40 levels were significantly elevated in
IPF patients than in control subjects (17.8 19.1 ng/ml vs.
0.3 0.9 ng/ml, respectively, p< 0.0001) (Fig. 2). In
smokers, BALF YKL-40 levels were higher in 5 IPF patients
than in 3 control subjects (20.1 10.8 ng/ml vs.
0.2 13.8 ng/ml), but statistical analysis was not done
because of small number of the control subjects. In non-
smokers, BALF YKL-40 levels were significantly elevated in
13 IPF patients than in 13 control subjects (16.9 3.0 ng/ml
vs. 0.4 3.0 ng/ml, respectively, p< 0.0001).
Correlation between YKL-40 levels and clinical
parameters in IPF
Spearman’s rank correlation analysis showed that serum
levels of YKL-40 correlated positively with those of KL-6
(Fig. 3A) and AaDO2, and negatively with DLco and PaO2
(Table 2); however, there was no significant correlation
between serum levels of YKL-40 and other clinical param-
eters, such as the serum levels of surfactant protein-D (SP-
D) (Fig. 3B) or those of lactate dehydrogenase (LDH). BALF
YKL-40 levels were significantly associated with none of the
clinical parameters. In addition, there was no significant
correlation between the serum and BALF levels of YKL-40 in
control subjects or IPF patients.
Expression of YKL-40 in lung tissue
Immunohistochemical staining of control lungs revealed
almost no expression of YKL-40 (Fig. 4A and B). Only very80
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Figure 2 BALF YKL-40 levels of IPF and control subjects. IPF
patients show significantly higher BALF YKL-40 levels than
normal control subjects (p< 0.0001). The bottom and top of
the box are always the 25th and 75th percentile (the lower and
upper quartiles, respectively), and the band near the middle of
the box is the 50th percentile (the mean). Also, The bottom
and top of the bars are the lowest data still within 1.5 inter-
quartile range (IQR) of the lower quartile, and the highest data
still within 1.5 IQR of the upper quartile. Any data not included
between the ranges are plotted as an outlier with a dot. BALF,
bronchoalveolar lavage fluid.faint staining for YKL-40 was observed in bronchiolar
epithelial cells of the normal lung. In IPF, the expression of
YKL-40 was found in the bronchiolar epithelial cells lining
honeycomb space (Fig. 4C and D). In addition, alveolar
macrophages accumulating in intraalveolar space adjacent
to fibrotic lesion strongly expressed YKL-40 (Fig. 4C and D).
No immunostaining was found in fibroblastic foci or smooth
muscle hyperplasia.Discussion
The present study is the first to demonstrate elevated
levels of YKL-40, human chitinase-like glycoprotein, in the
serum and BALF of IPF patients, with a significant correla-
tion between its serum levels and clinical parameters,
including PaO2, AaDO2, DLco, and serum concentrations of
KL-6. Additionally, enhanced expression of YKL-40 protein
was found in bronchiolar epithelial cells and alveolar
macrophages adjacent to fibrotic lesions by immunohisto-
chemistry. These data suggest that increased expression of
YKL-40 in the lung may be associated with fibrotic process
in IPF.
Although the detailed biological function of YKL-40 has
not been fully elucidated, recent studies have shown that
this glycoprotein has an important role in tissue remodeling
processes leading to fibrosis. YKL-40 potently promotes the
growth of fibroblasts, endothelial cells, synovial cells, and
chondrocytes.7e9,13e15 In addition, YKL-40 specifically binds
to type I collagen and stimulates its fibril formation.16 In
liver fibrosis, increased YKL-40 mRNA and protein were
found in fibrotic liver tissues, regardless of its etiology.17
Patients with moderate to severe liver fibrosis have been
shown to have an elevated level of serum YKL-40, which
correlates with disease activity and prognosis, suggesting
that YKL-40 is a useful biomarker in fibrotic liver
diseases.6,18 Moreover, increased levels of serum YKL-40
were shown to be related to joint destruction in rheuma-
toid arthritis.19
In the lung, a recent study showed elevated serum YKL-
40 levels in patients with severe asthma, and its levels
correlated with thickening of the subepithelial basement
membrane and pulmonary function.10 Interestingly, an
increase in serum YKL-40 was also found in sarcoidosis and
systemic sclerosis with pulmonary involvement.20e22 In
pulmonary sarcoidosis, Johansen et al. reported that serum
YKL-40 is a potential biomarker of disease activity and
ongoing fibrosis.20 Consistent with this, Kruit et al. also
demonstrated that increased YKL-40 levels were related to
the development of pulmonary fibrosis in sarcoidosis.21 In
systemic sclerosis (SSc), the levels of serum YKL-40 was
shown to be significantly higher in SSc patients with
pulmonary fibrosis than in those without it.22 More recently,
Le´utuve´ et al. reported that current smokers with COPD
had increased levels of serum and BALF YKL-40, which was
associated with airflow limitation.23 In vitro study also
demonstrated that YKL-40 augmented the production of
proinflammatory and fibrogenic chemokines, such as
interleukin-8 (IL-8) and monocyte chemotactic protein-1
(MCP-1) from alveolar macrophages.23 They concluded
that YKL-40 is up-regulated in current smokers with COPD,
in whom it may be attributable to tissue remodeling and
Figure 3 Correlation between serum YKL-40 levels, and clinical markers and BALF YKL-40 levels in IPF. Spearman’s rank
correlation analysis shows that serum levels of YKL-40 correlated positively with those of KL-6 (rZ 0.3096, pZ 0.0135) (A). There
is no significant correlation between serum levels of YKL-40 and those of SP-D or those of BALF (rZ 0.0550, pZ 0.6955; rZ 0.2500,
pZ 0.5887, respectively) (B and C). YKL-40 levels of serum and BALF were simultaneously measured in seven patients. SP-D,
surfactant protein-D, BALF, bronchoalveolar lavage fluid.
1208 K. Furuhashi et al.inflammation. Taken together, these findings suggest that,
besides etiology, YKL-40 can be increased under patholog-
ical conditions leading to chronic inflammation and tissue
remodeling in the lung. In the present study, we found that
YKL-40 levels in the serum and BALF were significantly
higher in IPF patients than in control subjects, and its
serum levels correlated with the clinical parameters. In
addition, immunohistochemical study showed an intense
expression of YKL-40 protein in the lung tissues of IPF
patients, but not in those of control subjects. Collectively,
these data suggest that increased production of YKL-40 in
IPF lungs contributes to tissue remodeling and fibrosis,
possibly through its fibrogenic capacity.
We found that serum levels of YKL-40 significantly corre-
lated with PaO2, AaDO2, DLco, and serum concentrationsTable 2 Correlation between serum and BALF YKL-40 levels an
Serum YKL-40
r P-valu
Serum
KL-6 0.3096 0.0135
SP-D 0.0550 0.6955
LDH 0.0875 0.5330
%VC 0.0543 0.7138
%DLco 0.4145 0.0254
PaO2 0.4167 0.0075
AaDO2 0.3891 0.0131
BALF, bronchoalveolar lavage fluid; SP-D, surfactant protein D; LDH, la
for carbon monoxide; AaDO2, alveolar-arterial oxygen difference.of KL-6. Those data on pulmonary function are related to the
disease severity of IPF and, in particular, DLco was shown to
be a prognostic factor of this disease.24 Serum levels of KL-6,
a MUC 1 mucin, are elevated in a variety of interstitial
pneumonias, including IPF.25 Its levels have been shown to be
a useful marker for disease activity and prognosis in IPF.26
Thus, our results suggest that serum levels of YKL-40 are
associatedwith disease severity and activity of IPF.However,
serum levels of YKL-40 failed to significantly correlate with
%VC. Our IPF patients had relatively high %VC (79.8 19.3),
which may be responsible, in part, for the poor correlation
between serum YKL-40 and %VC. On the other hand, YKL-40
levels in BALF did not significantly correlate to any clinical
parameters. The reason for this is unclear, but several
explanations are considered. First, the number of IPFd clinical parameters.
BALF YKL-40
e r P-value
0.3887 0.1231
0.0898 0.7409
0.1925 0.4591
0.1222 0.6520
0.0857 0.8717
0.0770 0.8025
0.7143 0.1108
ctate dehydrogenase; VC, vital capacity; DLco, diffusion capacity
Figure 4 Immunohistochemical staining for YKL-40 in surgical lung biopsy specimens from control subjects (A: original magni-
fication 100; B: 200) and IPF patients (C: original magnification 100; D: 200). Very faint staining for YKL-40 is observed in
bronchiolar epithelial cells of control lung. In IPF lung, the expression of YKL-40 is found in bronchiolar epithelial cells lining
honeycomb space (Fig. 4C) and alveolar macrophages accumulating in intraalveolar space adjacent to fibrotic lesions (Fig. 4D).
YKL-40 in serum and lung of patients with IPF 1209undergoing BAL was small. Second, YKL-40 levels measured
were much lower in BALF than in serum, suggesting that this
protein was not greatly released into alveolar space. Further
study, including a larger number of BAL specimens, will be
required to confirm these.
To elucidate YKL-40-producing cells in IPF lungs, we next
performed immunohistochemistry with a YKL-40-specific
antibody. We found that YKL-40 protein was expressed in
bronchiolar epithelial cells and alveolar macrophages in
fibrotic areas of IPF lungs. In particular, alveolar macro-
phages had intense expression of YKL-40. In contrast,
normal lungs had almost no positive staining for YKL-40.
Consistent with our observations, Chupp et al. showed the
intense expression of YKL-40 protein in alveolar macro-
phages as well as bronchial epithelial cells in patients with
severe asthma, and a significant correlation between the
median number of YKL-40-positive cells in subepithelial
areas and the severity of asthma.10 A recent study by
Le´utuve´ et al. also demonstrated strong staining for YKL-40
in alveolar macrophages obtained from current smokers
with COPD, but not in those from non-smokers.23 These
observations suggest that alveolar macrophages are the
major cell source of YKL-40 in the lung under pathological
conditions leading to tissue remodeling, and bronchiolar
epithelial cells also produce YKL-40 to a lesser extent.
There are several limitations to the present study.
Although this study included a relatively large number of
IPF patients, the sample size was still small when deter-
mining the definite clinical significance of YKL-40
measurements in IPF. Our study subjects had a great male
predominance. Although we served age- and gender-matched subjects as a control, our results may not fully
reflect general population of IPF patients. Additionally,
because the observation period of our patients was rela-
tively short (3.2 1.3 years), we could not clarify the true
relationship between YKL-40 levels and prognosis. Addi-
tional studies in a longitudinal setting of a larger IPF pop-
ulation will further address these issues.
In conclusion, we showed that YKL-40 is elevated in the
circulation and lungs of IPF patients. In addition, serum
levels of YKL-40 were significantly associated with clinical
parameters of IPF. Thus, the present study provides new
knowledge about the potential role of YKL-40 in IPF that
contributes to further understanding of its pathophysiology.
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